FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2161384285> ?p ?o ?g. }

• W2161384285 endingPage "252" @default.
• W2161384285 startingPage "248" @default.
• W2161384285 abstract "Darunavir (DRV) is the latest protease inhibitor (PI) to be approved for antiretroviral-naive and -experienced HIV-infected patients. We examined virologic and immunologic outcomes of highly antiretroviral-experienced patients with triple-class drug resistance receiving DRV/r-based regimens, and attempted to identify factors predictive of virologic success. We studied patients beginning a ritonavir-boosted DRV (DRV/r 600/100 mg twice daily)-containing regimen. Virologic success was defined as plasma viral load (pVL) < 50 copies/ml at week 36. We studied 62 patients with very severe immunodeficiency (CDC stage C in 69% of cases; median CD4 cell nadir 12/mm3). They had previously received a median of four PI and had extensive PI resistance, with a median of three major PI and two DRV resistance mutations. The baseline median pVL and CD4 cell count values were 4.6 log10 and 150/mm3. At week 36, pVL had fallen by 2.6 log10 and the CD4 cell count had risen by 123 cells/mm3. The virologic success rate was 55% overall, and was improved by concomitant first use of enfuvirtide (67%), raltegravir (69%) or etravirine (75%). Virologic success was independently associated with fewer major PI mutations, previous tipranavir exposure, and concomitant first use of enfuvirtide or raltegravir. In these highly antiretroviral-experienced patients with triple-class drug resistance, virologic success of DRV-containing regimens was mainly associated with the use of new drug classes and/or fully active drugs. Interestingly, previous tipranavir failure did not undermine the efficacy of DRV, confirming the low level of cross-resistance and, probably, distinct resistance profiles between DRV and tipranavir." @default.
• W2161384285 created "2016-06-24" @default.
• W2161384285 creator A5004847957 @default.
• W2161384285 creator A5008823640 @default.
• W2161384285 creator A5009181226 @default.
• W2161384285 creator A5014686694 @default.
• W2161384285 creator A5022180654 @default.
• W2161384285 creator A5028549285 @default.
• W2161384285 creator A5036677523 @default.
• W2161384285 creator A5039745057 @default.
• W2161384285 creator A5041701435 @default.
• W2161384285 creator A5051621566 @default.
• W2161384285 creator A5052655394 @default.
• W2161384285 creator A5061527531 @default.
• W2161384285 date "2010-03-01" @default.
• W2161384285 modified "2023-09-26" @default.
• W2161384285 title "Factors predictive of successful darunavir/ritonavir-based therapy in highly antiretroviral-experienced HIV-1-infected patients (the DARWEST study)" @default.
• W2161384285 cites W1530874315 @default.
• W2161384285 cites W1965922975 @default.
• W2161384285 cites W1966196773 @default.
• W2161384285 cites W1970117368 @default.
• W2161384285 cites W1983837630 @default.
• W2161384285 cites W1993148503 @default.
• W2161384285 cites W1995364703 @default.
• W2161384285 cites W2003948551 @default.
• W2161384285 cites W2007166840 @default.
• W2161384285 cites W2023770186 @default.
• W2161384285 cites W2060969737 @default.
• W2161384285 cites W2084487317 @default.
• W2161384285 cites W2103513664 @default.
• W2161384285 cites W2139167304 @default.
• W2161384285 cites W2139772076 @default.
• W2161384285 cites W2148788176 @default.
• W2161384285 cites W2156933277 @default.
• W2161384285 cites W2157791496 @default.
• W2161384285 cites W2163808834 @default.
• W2161384285 cites W4241267536 @default.
• W2161384285 doi "https://doi.org/10.1016/j.jcv.2009.12.022" @default.
• W2161384285 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20097121" @default.
• W2161384285 hasPublicationYear "2010" @default.
• W2161384285 type Work @default.
• W2161384285 sameAs 2161384285 @default.
• W2161384285 citedByCount "14" @default.
• W2161384285 countsByYear W21613842852012 @default.
• W2161384285 countsByYear W21613842852013 @default.
• W2161384285 countsByYear W21613842852014 @default.
• W2161384285 countsByYear W21613842852015 @default.
• W2161384285 countsByYear W21613842852018 @default.
• W2161384285 countsByYear W21613842852020 @default.
• W2161384285 crossrefType "journal-article" @default.
• W2161384285 hasAuthorship W2161384285A5004847957 @default.
• W2161384285 hasAuthorship W2161384285A5008823640 @default.
• W2161384285 hasAuthorship W2161384285A5009181226 @default.
• W2161384285 hasAuthorship W2161384285A5014686694 @default.
• W2161384285 hasAuthorship W2161384285A5022180654 @default.
• W2161384285 hasAuthorship W2161384285A5028549285 @default.
• W2161384285 hasAuthorship W2161384285A5036677523 @default.
• W2161384285 hasAuthorship W2161384285A5039745057 @default.
• W2161384285 hasAuthorship W2161384285A5041701435 @default.
• W2161384285 hasAuthorship W2161384285A5051621566 @default.
• W2161384285 hasAuthorship W2161384285A5052655394 @default.
• W2161384285 hasAuthorship W2161384285A5061527531 @default.
• W2161384285 hasConcept C126322002 @default.
• W2161384285 hasConcept C142462285 @default.
• W2161384285 hasConcept C143998085 @default.
• W2161384285 hasConcept C147483822 @default.
• W2161384285 hasConcept C159047783 @default.
• W2161384285 hasConcept C195616568 @default.
• W2161384285 hasConcept C203014093 @default.
• W2161384285 hasConcept C2776258796 @default.
• W2161384285 hasConcept C2776694085 @default.
• W2161384285 hasConcept C2778037500 @default.
• W2161384285 hasConcept C2779182219 @default.
• W2161384285 hasConcept C2779298103 @default.
• W2161384285 hasConcept C2779384505 @default.
• W2161384285 hasConcept C2780345285 @default.
• W2161384285 hasConcept C2780404665 @default.
• W2161384285 hasConcept C2780775027 @default.
• W2161384285 hasConcept C2781143361 @default.
• W2161384285 hasConcept C2781413609 @default.
• W2161384285 hasConcept C2993143319 @default.
• W2161384285 hasConcept C3013748606 @default.
• W2161384285 hasConcept C71924100 @default.
• W2161384285 hasConcept C90924648 @default.
• W2161384285 hasConceptScore W2161384285C126322002 @default.
• W2161384285 hasConceptScore W2161384285C142462285 @default.
• W2161384285 hasConceptScore W2161384285C143998085 @default.
• W2161384285 hasConceptScore W2161384285C147483822 @default.
• W2161384285 hasConceptScore W2161384285C159047783 @default.
• W2161384285 hasConceptScore W2161384285C195616568 @default.
• W2161384285 hasConceptScore W2161384285C203014093 @default.
• W2161384285 hasConceptScore W2161384285C2776258796 @default.
• W2161384285 hasConceptScore W2161384285C2776694085 @default.
• W2161384285 hasConceptScore W2161384285C2778037500 @default.
• W2161384285 hasConceptScore W2161384285C2779182219 @default.
• W2161384285 hasConceptScore W2161384285C2779298103 @default.
• W2161384285 hasConceptScore W2161384285C2779384505 @default.
• W2161384285 hasConceptScore W2161384285C2780345285 @default.

• next